Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial

Circulation

Volumn 108, Issue 10, 2003, Pages 1176-1183

  Mahaffey, Kenneth W ^a   Granger, Christopher B ^a   Nicolau, Jose C ^b   Ruzyllo, Witold ^c   Weaver, W Douglas ^d   Theroux, Pierre ^e   Hochman, Judith S ^f   Filloon, Thomas G ^g   Mojcik, Christopher F ^h   Todaro, Thomas G ^g   Armstrong, Paul W ⁱ  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTE OF CARDIOLOGY   (Poland)

^d HENRY FORD HOSPITAL   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h ALEXION PHARMACEUTICALS   (United States)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Fibrinolysis; Inflammation; Myocardial infarction; Reperfusion

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT COMPONENT C5; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; MONOCLONAL ANTIBODY; PEXELIZUMAB; STATINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOPLASTY; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ELECTROCARDIOGRAM; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART RUPTURE; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STROKE;

AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CHEMOTHERAPY, ADJUVANT; COMPLEMENT C5; CREATINE KINASE; CREATINE KINASE, MB FORM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 0041732120     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000087404.53661.F8     Document Type: Article

References (29)

1. The GUSTO-III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
2. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.
3. The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716-722.
4. The ASSENT-3 Investigators. Efficacy, and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-613.
5. Yasuda M, Takeuchi K, Hiruma M, et al. The complement system in ischemic heart disease. Circulation. 1990;81:156-163.
6. Pinckard RN, Olson MS, Giclas PC, et al. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest. 1975;56:740-750.
7. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95-105.
8. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259-2267.
9. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100:2499-2506.
10. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389-1401.
11. Vollmer RT, Christenson RH, Reimer K, et al. Temporal creatine kinase curves in acute myocardial infarction: implications of a good empiric fit with the log-normal function. Am J Clin Pathol. 1993;100:293-298.
12. Anzai T, Yoshikawa T, Shiraki H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997;96:778-784.
13. Mollnes TE, Tambs KE, Myreng Y, et al. Acute phase reactants and complement activation in patients with acute myocardial infarction. Complement. 1988;5:33-39.
14. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a Thrombolysis In Myocardial Infarction 10 substudy. Circulation. 2000;102:2329-2334.
15. Hammerman H, Kloner RA, Hale S, et al. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function. Circulation. 1983;68:446-452.
16. Silverman HS, Pfeifer MP. Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial infarction. Am J Cardiol. 1987;59:363-364.
17. Brown EJ Jr, Kloner RA, Schoen FJ, et al. Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am J Cardiol. 1983;51:877-883.
18. Hammerman H, Kloner RA, Schoen FJ, et al. Indomethacin-induced scar thinning after experimental myocardial infarction. Circulation. 1983;67:1290-1295.
19. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Circulation. 2001;104:2778-2783.
20. Pinckard RN, O'Rourke RA, Crawford MH, et al. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest. 1980;66:1050-1056.
21. Stahl GL, Amsterdam EA, Symons JD, et al. Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. Circ Res. 1990;66:1103-1111.
22. de Zwaan C, Kleine AH, Diris JC, et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J. 2002;23:1670-1677.
23. Sobel BE, Bresnahan GF, Shell WE, et al. Estimation of infarct size in man and its relation to prognosis. Circulation. 1972;46:640-648.
24. Bleifeld W, Mathey D, Hanrath P, et al. Infarct size estimated from serial serum creatine phosphokinase in relation to left ventricular hemodynamics. Circulation. 1977;55:303-311.
25. Magnani B, Melandri G. The role of infarct size in early and late mortality. J Cardiovasc Pharmacol. 1989;14:S25-S28.
26. Grande P, Hansen BF, Christiansen C, et al. Acute myocardial infarct size estimated by serum CK-MB determinations: clinical accuracy and prognostic relevance utilizing a practical modification of the isoenzyme approach. Am Heart J. 1981;101:582-586.
27. van der Laarse A, Vermeer F, Hermens WT, et al. Effects of early intracoronary streptokinase on infarct size estimated from cumulative enzyme release and on enzyme release rate: a randomized trial of 533 patients with acute myocardial infarction. Am Heart J. 1986;112:672-681.
28. Baardman T, Hermens WT, Lenderink T, et al. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. Eur Heart J. 1996;17:237-246.
29. de Boer MJ, Suryapranata H, Hoorntje JC, et al. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction. Circulation. 1994;90:753-761.